← Leaderboards
Luca Cartegni
Rutgers Biomedical And Health Sciences
$4,439,420
Attributed
$4,439,420
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $722.6K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,439,420 · 4
By mechanism
R01$3,572,437 · 2
R21$866,983 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionPropertyOncogenicRna SplicingDesignAlternative SplicingIn VitroMalignant NeoplasmsPolyadenylationProtein IsoformsCellsChemistryTumorVariantBiologicalDominant-Negative MutationLengthLigandsDrug ResistancePlayProgramsBiodistributionAntisense OligonucleotidesCessation Of Life
Grant awards (17)
Targeting Refractory EGFR-Driven Tumors By Induction Of Dominant-Negative EGFR Splicing Variants$343,344
R01 · FY2024 · CA · contact PI
Targeting Refractory EGFR-Driven Tumors By Induction Of Dominant-Negative EGFR Splicing Variants$354,099
R01 · FY2023 · CA · contact PI
Therapeutic potential of antitumorigenic soluble MET variants induced by splicing interference$352,564
R01 · FY2023 · CA · contact PI
Targeting Refractory EGFR-Driven Tumors By Induction Of Dominant-Negative EGFR Splicing Variants$354,012
R01 · FY2022 · CA · contact PI
Therapeutic potential of antitumorigenic soluble MET variants induced by splicing interference$352,564
R01 · FY2022 · CA · contact PI
Therapeutic potential of antitumorigenic soluble MET variants induced by splicing interference$1
R01 · FY2021 · CA · contact PI
Targeting Refractory EGFR-Driven Tumors By Induction Of Dominant-Negative EGFR Splicing Variants$1
R01 · FY2021 · CA · contact PI
Targeting Refractory EGFR-Driven Tumors By Induction Of Dominant-Negative EGFR Splicing Variants$361,147
R01 · FY2020 · CA · contact PI
Therapeutic potential of antitumorigenic soluble MET variants induced by splicing interference$359,759
R01 · FY2020 · CA · contact PI
Targeting Refractory EGFR-Driven Tumors By Induction Of Dominant-Negative EGFR Splicing Variants$373,641
R01 · FY2019 · CA · contact PI
Therapeutic potential of antitumorigenic soluble MET variants induced by splicing interference$348,965
R01 · FY2019 · CA · contact PI
Therapeutic potential of antitumorigenic soluble MET variants induced by splicing interference$372,340
R01 · FY2018 · CA · contact PI
Controlled premature termination of translation to generate designated truncated$194,684
R21 · FY2014 · CA · contact PI
Controlled premature termination of translation to generate designated truncated$190,139
R21 · FY2013 · CA · contact PI
Controlled premature termination of translation to generate designated truncated$34,225
R21 · FY2013 · CA · contact PI
Controlled premature termination of translation to generate designated truncated$238,685
R21 · FY2012 · CA · contact PI
Development-HTS Assay-Identify Specific Alternative(RMI)$209,250
R21 · FY2005 · NS